Management of established rheumatoid arthritis with an emphasis on pharmacotherapy

Best Practice and Research: Clinical Rheumatology

Volumn 21, Issue 1, 2007, Pages 43-57

  Blom, M ^a   van Riel, P L C M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

combination strategy; established; pharmacological treatment; rheumatoid arthritis

Indexed keywords

ABATACEPT; ADALIMUMAB; ANALGESIC AGENT; ANTIRHEUMATIC AGENT; AZATHIOPRINE; CHLOROQUINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; FOLIC ACID; GASTROINTESTINAL AGENT; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE DERIVATIVE; PARACETAMOL; PENICILLAMINE; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR DERIVATIVE;

CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMORBIDITY; DISEASE ACTIVITY; DISEASE COURSE; DRUG MEGADOSE; DYSLIPIDEMIA; GASTROINTESTINAL DISEASE; HEALTH ECONOMICS; HOMOCYSTINURIA; HUMAN; HYPERTENSION; JOINT INJURY; KIDNEY DISEASE; LIFE EXPECTANCY; MONOTHERAPY; MORTALITY; OCCUPATIONAL THERAPY; PHYSICAL DISABILITY; PHYSIOTHERAPIST; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; REVIEW; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COMORBIDITY; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; HUMANS; METHOTREXATE; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); PROGNOSIS; QUALITY OF LIFE;

EID: 33847663831     PISSN: 15216942     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.berh.2006.09.002     Document Type: Review

References (116)

1. Bresnihan B. Pathogenesis of joint damage in rheumatoid arthritis. The Journal of Rheumatology 26 (1999) 717-719
2. Hochberg M.C. Adult and juvenile rheumatoid arthritis: current epidemiologic concepts. Epidemiologic Reviews 3 (1981) 27-44
3. Pincus T. Long-term outcomes in rheumatoid arthritis. British Journal of Rheumatology 34 (1995) 59-73
4. Plant M.J., Jones P.W., Saklatvala J., et al. Patterns of radiological progression in early rheumatoid arthritis: results of an 8 year prospective study. The Journal of Rheumatology 25 (1998) 417-426
5. Harle P., Bongartz T., Scholmerich J., et al. Predictive and potentially predictive factors in early arthritis: a multidisciplinary approach. The Journal of Rheumatology 44 (2005) 426-433
6. Visser H., le Cessie S., Vos K., et al. How to diagnose rheumatoid arthritis early: a prediction model for persistent (erosive) arthritis. Arthritis and Rheumatism 46 (2002) 357-365
7. Bykerk V.P., and Keystone E.C. What are the goals and principles of management in the early treatment of rheumatoid arthritis?. Best Practice & Research. Clinical Rheumatology 19 (2005) 147-161
8. van der Heide A., Jacobs J.W., Bijlsma J.W., et al. The effectiveness of early treatment with second line anti-rheumatic drugs. A randomised controlled trial. Annals of Internal Medicine 124 (1996) 699-707
9. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis and Rheumatism 46 (2002) 328-346
10. Goekoop-Ruiterman Y.P.M., de Vries-Bouwstra J.K., Allaart C.F., et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study). Arthritis and Rheumatism 52 (2005) 3381-3390
11. Welsing P.M., van Gestel A.M., Swinkels H.L., et al. The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis. Arthritis and Rheumatism 44 (2001) 2009-2017
12. Prevoo M.L., van Gestel A.M., van 't Hof M.A., et al. Remission in a prospective study of patients with rheumatoid arthritis. American Rheumatism Association preliminary remission criteria in relation to the disease activity score. British Journal of Rheumatology 35 (1996) 1101-1105
13. Drossaers-Bakker K.W., de Buck M., van Zeben D., et al. Long-term course and outcome of functional capacity in rheumatoid arthritis. Arthritis and Rheumatism 42 (1999) 1854-1860
14. Guillemin F., Suurmeijer T., Krol B., et al. Functional disability in early rheumatoid arthritis: description and risk factors. The Journal of Rheumatology 21 (1994) 1051-1055
15. van Leeuwen M.A., van der Heijde D.M.F.M., van Rijswijk M.H., et al. Interrelationship of outcome measures and process variables in early rheumatoid arthritis. A comparison of radiological damage, physical disability, joint count, and acute phase reactants. The Journal of Rheumatology 21 (1994) 425-429
16. Welsing P.M., Landewe R.B., van Riel P.L., et al. The relationship between disease activity and radiologic progression in patients with rheumatoid arthritis: a longitudinal analysis. Arthritis and Rheumatism 50 (2004) 2082-2093
17. van der Heijde D.M., van Leeuwen M.A., van Riel P.L., and van de Putte L.B. Radiographic progression on radiographs of hands and feet during the first 3 years of rheumatoid arthritis measured according to Sharp's method (van der Heijde modification). The Journal of Rheumatology 22 (1995) 1792-1796
18. Fuchs H.A., Kaye J.J., Callahan L.F., et al. Evidence of significant radiographic damage in rheumatoid arthritis within the first 2 years of disease. The Journal of Rheumatology 16 (1989) 585-591
19. Buckari M., Harrison B., Lunt M., et al. Time to first occurrence of erosions in inflammatory polyarthritis: results from a prospective community-based study. Arthritis and Rheumatism 60 (2001) 956-961
20. Fex E., Jonsson K., and Eberhard K. Development of radiographic damage during the first 5-6 years of rheumatoid arthritis. A prospective follow-up study of a Swedish cohort. British Journal of Rheumatology 35 (1996) 1106-1115
21. Wolfe F., and Sharp J.T. Radiographic outcome of recent-onset rheumatoid arthritis: a 19-year study of radiographic progression. Arthritis and Rheumatism 41 (1998) 1571-1582
22. Uhlig T., Smedstad L.M., Vaglum P., et al. The course of rheumatoid arthritis and predictors of psychological, physical and radiographic outcome after 5 years of follow-up. Rheumatology (Oxford, England) 39 (2000) 732-741
23. Hulsmans H.M.J., Jacobs J.W.G., van der Heijde D.M.F.M., et al. The course of radiologic damage during the first six years of rheumatoid arthritis. Arthritis and Rheumatism 43 (2000) 1927-1940
24. Scott D.L., Pugner K., and Kaarlea K. The links between joint damage and disability in rheumatoid arthritis. Rheumatology 39 (2000) 122-132
25. Molenaar E.T., Voskuyl A.E., Dinant H.J., et al. Progression of radiologic damage in patients with rheumatoid arthritis in clinical remission. Arthritis and Rheumatism 50 (2004) 36-42
26. Guillemin F., Gerard N., and van Leeuwen M. Prognostic factors for joint destruction in rheumatoid arthritis: a prospective longitudinal study of 318 patients. The Journal of Rheumatology 30 (2003) 2585-2589
27. Scott D.L. Radiological progression in established rheumatoid arthritis. The Journal of Rheumatology 31 supplement 69 (2004) 55-65
28. Kroot E.J.J.A., De Jong B.A.W., van Leeuwen M.A., et al. The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis and Rheumatism 43 (2000) 1831-1835
29. Lindqvist E., Eberhardt K., Bendtzen K., et al. Prognostic laboratory markers of joint damage in rheumatoid arthritis. Annals of the Rheumatic Diseases 64 (2005) 196-201
30. Smolen J.S., Han C., Bala M., et al. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement. Arthritis and Rheumatism 52 (2005) 1020-1030
31. Scott D.L., Smith C., and Kingsley G. What are the consequences of early rheumatoid arthritis for the individual?. Best Practice & Research. Clinical Rheumatology 19 (2005) 117-136
32. Pollard L.C., Choy E.H., Gonzalez J., et al. Fatigue in rheumatoid arthritis reflects pain, not disease activity. Rheumatology (Oxford, England) 45 (2006) 885-889
33. Gabriel S.E., Crowson C.S., Maradit Kremers H., et al. Survival in rheumatoid arthritis; a population-based analysis of trends over 40 years. Arthritis and Rheumatism 48 (2003) 54-58
34. Kroot E.J., van Leeuwen M.A., van Rijswijk M.H., et al. No increased mortality in patients with rheumatoid arthritis: up to 10 years of follow up from disease onset. Annals of the Rheumatic Diseases 59 (2000) 954-958
35. Callahan L.F., and Pincus T. Mortality in the rheumatic diseases. Arthritis Care and Research 8 (1995) 229-241
36. Boers M., Dijkmans B., Gabriel S., et al. Making an impact on mortality in rheumatoid arthritis; targeting cardiovascular comorbidity. Arthritis and Rheumatism 50 (2004) 1734-1739
37. Gabriel S., Crowson C., and O'Fallon M. Comorbidity in arthritis. The Journal of Rheumatology 26 (1999) 2475-2479
38. Kroot E.F., van Gestel A.M., Swinkels H., et al. Chronic comorbidity in patients with early rheumatoid arthritis: a descriptive study. The Journal of Rheumatology 28 (2001) 1511-1517
39. Berkanovic E., and Hurwicz M.L. Rheumatoid arthritis and comorbidity. The Journal of Rheumatology 17 (1990) 888-892
40. Pincus T., Brooks R.H., and Callahan L.F. Prediction of long-term mortality in patients with rheumatoid arthritis according to simple questionnaire and joint count measures. Annals of Internal Medicine 120 (1994) 26-34
41. Maradit-Kremers H., Nicola P.J., Crowson C.S., et al. Cardiovascular death in rheumatoid arthritis; a population-based study. Arthritis and Rheumatism 52 (2005) 722-732
42. Dechant S.A., and Matteson E.L. Managing comorbidity risks in rheumatoid arthritis. Current Opinion in Rheumatology 16 (2004) 177-179
43. Wållberg-Jonsson S., Öhman M.-L., and Rantapää-Dahlqvist S. Which factors are related to the presence of atherosclerosis in rheumatoid arthritis?. Scandinavian Journal of Rheumatology 33 (2004) 373-379
44. Solomon D.H., Karlson E.W., Rimm E.B., et al. Cardiovascular morbidity and mortality in women diagnoses with rheumatoid arthritis. Circulation 107 (2003) 1303-1307
45. Chung C.P., Oeser A., Raggi P., et al. Increased coronary-artery atherosclerosis in rheumatoid arthritis: relationship to disease duration and cardiovascular risk factors. Arthritis and Rheumatism 52 (2005) 3045-3053
46. Baecklund E., Iliadou A., Askling J., et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis and Rheumatism 54 (2006) 692-701
47. Wolfe F., Mitchell D.M., Sibley J.T., et al. The mortality of rheumatoid arthritis. Arthritis and Rheumatism 37 (1994) 481-494
48. Riise T., Jacobsen B.K., Gran J.T., et al. Total mortality is increased in rheumatoid arthritis. A 17-year prospective study. Clinical Rheumatology 20 (2001) 123-127
49. Navarro-Cano G., del Rincón I., and Pogosian S. Association of mortality with disease severity in rheumatoid arthritis, independent of comorbidity. Arthritis and Rheumatism 48 (2003) 2425-2433
50. Peltomaa R., Paimela L., Kautiainen H., and Leirisalo-Repo M. Mortality in patients with rheumatoid arthritis treated actively from the time of diagnosis. Annals of the Rheumatic Diseases 61 (2002) 889-894
51. Rat A.-C., and Boissier M.-C. Rheumatoid arthritis: direct and indirect costs. Joint, Bone, Spine: Revue du Rhumatisme 71 (2004) 518-524
52. Pugner K.M., Scott D.I., Holmes J.W., and Hieke K. The costs of rheumatoid arthritis: an international long-term view. Seminars in Arthritis and Rheumatism 29 (2000) 305-320
53. Cooper N.J. Economic burden of rheumatoid arthritis: a systematic review. Rheumatology (Oxford, England) 39 (2000) 28-33
54. Welsing P.M.J., Kievit W., Laan R.F.J.M., and Severens J.L. Quality of life and costs for different treatment strategies for rheumatoid arthritis. Expert Review of Pharmacoeconomics and Outcomes Research 5 (2005) 395-410
55. Verstappen S.M.M., Verkleij H., Bijlsma J.W.J., et al. Determinants of direct costs in Dutch rheumatoid arthritis patients. Annals of the Rheumatic Diseases 63 (2004) 817-824
56. Jones G., Halbert J., Crotty M., et al. The effect of treatment on radiological progression in rheumatoid arthritis: a systematic review of randomized placebo-controlled trials. Rheumatology (Oxford, England) 42 (2003) 6-13
57. Maini R., St Clair E.W., Breedveld F., et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 354 (1999) 1932-1939
58. Klareskog L., van der Heijde D., de Jage J.P., et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 363 (2004) 675-681
59. Keystone E.C., Kavanaugh A.F., Sharp J.T., et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis and Rheumatism 50 (2004) 1400-1411
60. Cohen S.B., Moreland L.W., Cush J.J., et al. A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. Annals of the Rheumatic Diseases 63 (2004) 1062-1068
61. Kremer J.M., Dougados M., Emery P., et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial. Arthritis and Rheumatism 52 (2005) 2229-2232
62. Edwards J.C.W., Szczepański L., Szechiński J., et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. New England Journal of Medicine 350 (2004) 2575-2581
63. Furst D.E., Breedveld F.C., Kalden J.R., et al. Updated consensus statement on biological agents specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005. Annals of the Rheumatic Diseases 64 (2005) iv2-iv14
64. Lipsky P.E., van der Heijde D.M., St Clair E.W., et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. The New England Journal of Medicine 343 (2000) 1594-1602
65. Finckh A., Simard J.F., Duryea J., et al. The effectiveness of anti-tumour necrosis factor therapy in preventing progressive radiographic joint damage in rheumatoid arthritis. Arthritis and Rheumatism 54 (2006) 54-59
66. Bijlsma J.W.J., van Everdingen A.A., Huisman M., et al. Glucocorticoids in rheumatoid arthritis: effects on erosions and bone. Annals of the New York Academy of Sciences 966 (2002) 82-90
67. Choy E.H., Kingsley G.H., Khoshaba B., et al. A two year randomised controlled trial of intramuscular depot steroids in patients with established rheumatoid arthritis who have shown an incomplete response to disease modifying antirheumatic drugs. Annals of the Rheumatic Diseases 64 (2005) 1288-1293
68. Choy E.H.S., Smith C., Doré C.J., and Scott D.L. A meta-analysis of the efficacy and toxicity of combining disease-modifying anti-rheumatic drugs in rheumatoid arthritis based on patient withdrawal. Rheumatology (Oxford, England) 44 (2005) 1414-1421
69. Landewe R.B., Boers M., Verhoeven A.C., et al. COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis and Rheumatism 46 (2002) 347-356
70. Korpela M., Laasonen L., Hannonen P., et al. Retardation of joint damage in patients with early rheumatoid arthritis by initial aggressive treatment with disease-modifying antirheumatic drugs. Arthritis and Rheumatism 50 (2004) 2072-2081
71. Van Riel P.L.C.M., Haagsma C.J., and Furst D.E. Pharmacotherapeutic combination strategies with disease-modifying antirheumatic drugs in established rheumatoid arthritis. Baillière's Best Practice & Research. Clinical Rheumatology 13 (1999) 687-700
72. Boers M., Verhoeven A.C., Markusse H.M., et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 350 (1997) 309-318
73. Pincus T., Yazici Y., Sokka T., et al. Methotrexate as the "anchor drug" for the treatment of early rheumatoid arthritis. Clinical and Experimental Rheumatology 21 supplement 31 (2003) S179-S185
74. Pincus T., O'Dell J.R., and Kremer J.M. Combination therapy with multiple disease-modifying antirheumatic drugs in rheumatoid arthritis: a preventive strategy. Annals of Internal Medicine 131 (1999) 768-774
75. Hochberg M.C., Tracy J.K., Hawkins-Holt M., et al. Comparison of the efficacy of the tumour necrosis factor alpha blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis. Annals of the Rheumatic Diseases 62 supplement II (2003) ii13-ii16
76. Van Vollenhoven R., Harju A., Brannemark S., and Klareskog L. Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor alpha blockers can make sense. Annals of the Rheumatic Diseases 62 (2003) 1195-1198
77. Kremer J.M., Genovese M.C., Cannon G.W., et al. Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate: a randomized, double-blind, placebo-controlled trial. Annals of Internal Medicine 137 (2002) 726-733
78. Sarzi-Puttini P., D'Ingianna E., Fumagalli M., et al. An open, randomized comparison study of cyclosporine A, cyclosporine A + methotrexate and cyclosprorine A + hydroxychloroquine in the treatment of early severe rheumatoid arthritis. Rheumatology International 25 (2005) 15-22
79. Lehman A.J., Esdaile J.M., Klinkhoff A.V., et al. A 48-week, randomized, double-blind, double-observer, placebo-controlled multicenter trial of combination methotrexate and intramuscular gold therapy in rheumatoid arthritis: results of the METGO study. Arthritis and Rheumatism 52 (2005) 1360-1370
80. Dougados M., Emery P., Lemmel E.M., et al. When a DMARD fails, should patients switch to sulfasalazine or add sulfasalazine to continuing leflunomide?. Annals of the Rheumatic Diseases 64 (2005) 44-51
81. Roj Kovich B., Hodinka L., Balint G., et al. Cyclosporine and sulphasalazine combination in treatment of early rheumatoid arthritis. Scandinavian Journal of Rheumatology 28 (1999) 216-221
82. Van den Borne B.E., Landewe R.B., Geoi H.S., et al. Combination therapy in recent rheumatoid arthritis: a randomised double blind trial of low dose cyclosporin to patients treated with low dose chloroquine. The Journal of Rheumatology 25 (1998) 1493-1498
83. Nelissen R.G.H.H. The impact of total joint replacement in rheumatoid arthritis. Best Practice & Research. Clinical Rheumatology 17 (2003) 831-846
84. Astin J.A., Beckner W., Soeken K., et al. Psychological interventions for rheumatoid arthritis: a meta-analysis of randomized controlled trials. Arthritis and Rheumatism 47 (2002) 291-302
85. Hawley D.J. Psycho-educational interventions in the treatment of arthritis. Baillère's Clinical Rheumatology 9 (1995) 803-823
86. Van den Ende C.H.M., Vliet Vlieland T.P.M., Munneke M., and Hazes J.M.W. Dynamic exercise therapy in rheumatoid arthritis: a systematic review. British Journal of Rheumatology 37 (1998) 677-687
87. Anderson J.J., Wells G., Verhoeven A.C., and Felson D.T. Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration. Arthritis and Rheumatism 43 (2000) 22-29
88. Maradit-Kremers H., Nicola P.J., Crowson C.S., et al. Patient, disease, and therapy-related factors that influence discontinuation of disease-modifying antirheumatic drugs: a population-based incidence cohort of patients with rheumatoid arthritis. The Journal of Rheumatology 33 (2006) 248-255
89. Hyrich K.L., Watson K.D., Silman S.J., et al. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford, England) (2006) 10.1093/rheumatology/kel149 [E-pub May 16 2006]
90. Padyukov L., Lampa J., Heimbürger M., et al. Genetic markers for the efficacy of tumour necrosis factor blocking therapy in rheumatoid arthritis. Annals of the Rheumatic Diseases 62 (2003) 526-529
91. Tutuncu Z., Kavanaugh A., Zvaifler N., et al. Fcγ receptor type IIIa polymorphisms influence treatment outcomes in patients with inflammatory arthritis treated with tumour necrosis factor α-blocking agents. Arthritis and Rheumatism 52 (2005) 2693-2696
92. Fransen J., Bernelot Moens H., Speyer I., and van Riel P.L.C.M. Effectiveness of systematic monitoring of rheumatoid arthritis disease activity in daily practice: a multicentre, cluster randomised controlled trial. Annals of the Rheumatic Diseases 64 (2005) 1294-1298
93. Grigor C., Capell H., Stirling A., et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 364 (2004) 263-269
94. Fries J.F. The hierarchy of outcome assessment. The Journal of Rheumatology 20 (1993) 546-547
95. Fries J.F., Spitz P., Kraines R.G., and Holman H.R. Measurement of patient outcome in arthritis. Arthritis and Rheumatism 23 (1980) 137-145
96. Fries J.F. Toward an understanding of patient outcome measurement. Arthritis and Rheumatism 26 (1983) 697-704
97. Felson D.T., Anderson J.J., Boers M., et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis and Rheumatism 36 (1993) 729-740
98. Goldsmith C.H., Boers M., Bombardier C., et al. for the OMERACT Committee. Criteria for clinically important changes in outcomes: development, scoring, and evaluation of the rheumatoid arthritis patient and trial profiles. The Journal of Rheumatology 20 (1993) 561-565
99. Felson D.T., Anderson J.J., Boers M., et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis and Rheumatism 38 (1995) 727-735
100. Van Gestel A.M., Prevoo M.L.L., van 't Hof M.A., et al. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Arthritis and Rheumatism 39 (1996) 34-40
101. Meenan R.F., Gertman P.M., and Mason J.H. Measuring health status in arthritis. The arthritis impact measurement scales. Arthritis and Rheumatism 23 (1980) 146-152
102. Spitz P.W., and Fries J.F. The present and future of comprehensive outcome measures for rheumatic diseases. Clinical Rheumatology 6 supplement 2 (1987) 105-111
103. Tugwell P., Bombardier C., Buchanan W.W., et al. The MACTAR Patient Preference Disability Questionnaire - an individualized functional priority approach for assessing improvement in physical disability in clinical trials in rheumatoid arthritis. The Journal of Rheumatology 14 (1987) 446-451
104. Fitzpatrick R., Newman S., Lamb R., and Shipley M. A comparison of measures of health status in rheumatoid arthritis. British Journal of Rheumatology 28 (1989) 201-206
105. Østergaard M., and Szkudlarek M. Imaging in rheumatoid arthritis - why MRI and ultrasonography can no longer be ignored. Scandinavian Journal of Rheumatology 32 (2003) 63-73
106. Sharp J.T., Lidsky M.D., Collins L.C., and Moreland J. Method of scoring the progression of radiologic changes in rheumatoid arthritis. Arthritis and Rheumatism 14 (1971) 706-720
107. Larsen A., Dale K., and Eek M. Radiographic evaluation of rheumatoid arthritis and related conditions by reference films. Acta Radiologica: Diagnosis 18 (1977) 481-491
108. van der Heijde D., van Riel P.L., Nuver-Zwart I.H., et al. Effects of hydroxychloroquine and sulfasalazine on progression of joint damage in rheumatoid arthritis. Lancet 1 (1989) 1036-1038
109. Rau R., and Herborn G. A modified version of Larsen's scoring method to assess radiologic changes in rheumatoid arthritis. The Journal of Rheumatology 22 (1995) 1976-1982
110. van der Heijde D., Dankert T., Nieman F., et al. Reliability and sensitivity to change of a simplification of the Sharp/van der Heijde radiological assessment in rheumatoid arthritis. Rheumatology (Oxford, England) 38 (1999) 941-947
111. Guillemin F., Billot L., Boini S., et al. Reproducibility and sensitivity to change of 5 methods for scoring hand radiographic damage in patients with rheumatoid arthritis. The Journal of Rheumatology 32 (2005) 778-786
112. van der Heijde D.M.F.M., van 't Hof M.A., van Riel P.L.C.M., and van de Putte L.B.A. Validity of single variables and indices to measure disease activity in rheumatoid arthritis. The Journal of Rheumatology 20 (1993) 538-541
113. Prevoo M.L., van 't Hof M.A., Kuper H.H., et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis and Rheumatism 38 (1995) 44-48
114. Smolen J.S., Breedveld F.C., Schiff M.H., et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford, England) 42 (2003) 244-257
115. Stucki G., Liang M.H., Stucki S., et al. Self-administered rheumatoid arthritis disease activity index (RADAI) for epidemiologic research. Psychometric properties and correlation with parameters of disease activity. Arthritis and Rheumatism 38 (1995) 795-798
116. Rau R., Wassenberg S., Herborn G., et al. A new method of scoring radiographic change in rheumatoid arthritis. The Journal of Rheumatology 25 (1998) 2094-2106